scholarly journals Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease

2018 ◽  
Vol 24 (1) ◽  
pp. 50-54 ◽  
Author(s):  
Scott S. Graves ◽  
Maura H. Parker ◽  
Diane Stone ◽  
George E. Sale ◽  
Smitha P.S. Pillai ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Graft Versus Host Disease ◽  
Antibody Treatment ◽  
Host Disease ◽  
Graft Versus Host ◽  
Inducible Costimulator ◽  
Monoclonal Antibody Treatment

Treatment of Steroid-Resistant Graft-Versus-Host Disease with Monoclonal Antibodies in Children.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5310-5310
Author(s):  
Tal Schechter ◽  
Samina Afzal ◽  
Yaron Finkelstein ◽  
Gideon Koren ◽  
John Doyle ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Partial Response ◽  
Graft Versus Host Disease ◽  
Complete Response ◽  
Antibody Treatment ◽  
Hematopoietic Stem ◽  
Steroid Resistant ◽  
Host Disease ◽  
Graft Versus Host

Abstract Acute graft-versus-host disease (aGVHD) carries a major risk of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). The prognosis is poor if aGVHD does not respond to corticosteroid treatment. Recently, monoclonal antibodies such as daclizumab, a humanized monoclonal IgG1, and infliximab, a chimeric monoclonal antibody that binds the precursor of tumor-necrosis factor-alfa, have shown promising results in the treatment of corticosteroid-resistant aGVHD. The reported response rate to monoclonal antibody therapy in adults with aGVHD reaches as high as 67%. Data describing the efficacy of monoclonal antibodies in children with corticosteroid-resistant aGVHD are limited. We conducted a retrospective analysis to evaluate the efficacy of daclizumab and/or infliximab in children diagnosed with steroid-resistant aGVHD in the Hospital for Sick Children, Toronto, from July 2002 to December 2005. Corticosteroid-resistant aGVHD was defined as aGVHD which did not respond or worsened after a minimum of 5 days of corticosteroid therapy. Complete response was defined as full recovery without any signs of aGVHD; partial response was defined as improvement of aGVHD symptoms in at least one organ without worsening in other organs. Sixteen children were treated for aGVHD, thirteen of them had aGVHD grade 3 or 4. The organs involved were gut (n=6), skin (n=4), liver (n=2) and multi-organ involvement (n=4). Thirteen children were given daclizumab; one was treated with infliximab and 2 children with their combination. Fourteen children received a full course of monoclonal antibodies for aGVHD. An additional child died after the first dose (from multi-organ failure) and one child developed reactive arthritis attributed to daclizumab. Seven of the 14 children (50%) who completed treatment responded: 5 had complete response and 2 had a partial response. Nine out of the 16 children died during the study period: 8 due to Transplant Related Mortality (TRM) and 1 due to relapse; three children developed fatal fungal infection and one had fatal adenovirus infection during or shortly after monoclonal antibody treatment. Median length of follow up in the remaining 7 patients was 18 months. We conclude that monoclonal antibodies were effective in the treatment of children with corticosteroid-resistant acute GVHD. The risk for infection, mainly fungal, was high.

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease

Blood ◽  
2004 ◽  
Vol 104 (8) ◽  
pp. 2603-2606 ◽  
Author(s):  
Marijke R. Canninga-van Dijk ◽  
Hanneke M. van der Straaten ◽  
Rob Fijnheer ◽  
Cornelus J. Sanders ◽  
Jan G. van den Tweel ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Autoimmune Diseases ◽  
Graft Versus Host Disease ◽  
Controlled Trial ◽  
Weekly Dose ◽  
Antibody Treatment ◽  
Laboratory Findings ◽  
Host Disease ◽  
Graft Versus Host ◽  
Anti Cd20

Abstract Chronic graft-versus-host disease (cGVHD) is an important determinant of long-term morbidity and mortality in allogeneic stem cell transplantation patients. Because cGVHD has clinical, histologic, and laboratory findings of autoimmune diseases and anti–B-cell therapy has shown efficacy in autoimmune diseases, we hypothesized that monoclonal anti-CD20 antibody therapy might improve patients with cGVHD. We treated 5 men and 1 woman with therapy-refractory extensive cGVHD with anti-CD20 monoclonal antibody. Intravenous infusion was given at a weekly dose of 375 mg/m2 for 4 weeks. In case of incomplete clinical response, additional courses of 4 weeks were given. Five patients responded to treatment with marked clinical, biochemical, and histologic improvement. One patient failed to respond. Anti-CD20 monoclonal antibody seems to be effective in cGVHD. A controlled trial is mandatory to confirm these results. The outcome of this study suggests a participating role of B cells in the pathogenesis of cGVHD.

PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE BY MONOCLONAL ANTIBODY TO INTERLEUKIN-2 RECEPTOR

The Lancet ◽  
1989 ◽  
Vol 333 (8650) ◽  
pp. 1333-1334 ◽  
Author(s):  
Didier Blaise ◽  
Dominique Maraninchi ◽  
Claude Mawas ◽  
AnneMarie Stoppa ◽  
Michel Hirn ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Graft Versus Host Disease ◽  
Interleukin 2 ◽  
Host Disease ◽  
Graft Versus Host ◽  
Interleukin 2 Receptor ◽  
Acute Graft

scholarly journals Protective effect of neutralizing anti-IL-18α monoclonal antibody on a mouse model of acute graft-versus-host disease

2015 ◽  
Vol 34 (4) ◽  
pp. 2031-2039 ◽  
Author(s):  
XIAOCUI LI ◽  
CUIPING ZHANG ◽  
WEI CHEN ◽  
BIN PAN ◽  
FANYUN KONG ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Mouse Model ◽  
Protective Effect ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft
Sign in / Sign up

Export Citation Format

Share Document